Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients : An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)
No Thumbnail Available
Date
2017-02-14
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Members of the APEX Investigators working group are listed in Web of Science database publication.
Keywords
anticoagulants, cardiology, cardiovascular diseases, intracranial hemorrhages, stroke, thrombosis, 3.2 Clinical medicine, 1.1. Scientific article indexed in Web of Science and/or Scopus database, SDG 3 - Good Health and Well-being
Citation
APEX Investigators & Stukena, I 2017, 'Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients : An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)', Circulation, vol. 135, no. 7, pp. 648-655. https://doi.org/10.1161/CIRCULATIONAHA.116.025427